Supreme Court Loosens Rule On What Processes Can Be Patented
This article was originally published in The Pink Sheet Daily
Executive Summary
To the relief of the biotechnology industry, the court rules in the Bilski case that a process need not be tied to a machine or transform an article to be patented.
You may also be interested in...
Personalized Medicine At Stake In Prometheus Patent Case, BIO Tells Supreme Court
The biotech and pharmaceutical industries oppose a broad ruling that would prevent patenting of medical processes and diagnostics. Mayo is challenging patents on the correlation between drug metabolites and proper dosage.
Eligible, But Probably Obvious: Prometheus Patents Critiqued In Government's Amicus Brief
The Solicitor General tells the Supreme Court that Prometheus' patents on a process for determining the proper dose of thiopurine drugs should have included "concrete treatment steps."
Eligible, But Probably Obvious: Prometheus Patents Critiqued In Government's Amicus Brief
The Solicitor General tells the Supreme Court that Prometheus' patents on a process for determining the proper dose of thiopurine drugs should have included "concrete treatment steps."